Ascelia Pharma

Ascelia Pharma announced today that the FDA has scheduled a Type A meeting for 9 September 2026 to discuss the Complete Response Letter issued in early July. The company has submitted a briefing package addressing each of the topics raised by the agency.

Following the FDA's Complete Response Letter for Orviglance and the subsequent publication of the redacted letter, we set out what the current share price implies, the scenarios we see into the Type A meeting, and our reading of the clinical issue at the centre of the case.

The FDA's Complete Response Letter (CRL) for Orviglance (NDA 220544) is now publicly accessible in redacted form through the FDA's openFDA transparency database. The letter's specifics raise the odds of a more demanding path to approval than previously indicated.

Ascelia Pharma provided a follow-up update yesterday, July 12, on the Complete Response Letter received on July 3. This is the first substantive detail the company has disclosed on the nature of the FDA's clinical concerns since the CRL, and it meaningfully narrows, though does not close, the range of scenarios we flagged in our July 3 note.